{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:00:34Z","timestamp":1773471634186,"version":"3.50.1"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2019,4,10]]},"abstract":"<jats:sec>\n<jats:title> Purpose:<\/jats:title>\n<jats:p>The purpose of this study was to develop a new PLGA based microsphere formulation aimed to release the olanzapine for the period of one month which will result in increased compliance. <\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> Microspheres loaded with olanzapine were prepared using oil in water emulsion and solvent evaporation technique. The microspheres were characterized by surface morphology, shape, size, bulk density, encapsulation efficiency, and Fourier transform infrared spectrometry. In vitro release studies were performed in phosphate buffer at 37\u00b0C and in vivo studies were conducted on male Sprague- Dawley rats. <\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The morphological results indicated that microspheres produced were having a smooth surface, spherical shape and the size in the range from 9.71 to 19.90 \u03bcm mean diameter. Encapsulation efficiency of olanzapine loaded microspheres was in the range of 78.53 to 96.12% and was affected by changing the ratio of lactic to glycolic acid in copolymer PLGA. The properties of PLGA and other formulation parameters had a significant impact on in vitro and in vivo release of drug from microspheres. In vitro release kinetics revealed that release of drug from microspheres is by both non-Fickian diffusion and erosion of PLGA polymer. In vivo data indicated an initial burst release and then sustained release depending on properties of PLGA, microsphere size, and bulk density. <\/jats:p><\/jats:sec>\n\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> This study indicates that microsphere formulations developed with PLGA (75:25) and PLGA (85:15) have provided a sufficient steady release of drug for at least 30 days and can be potential candidates for 30-day depot injection drug delivery of olanzapine.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1567201816666181227105930","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T08:12:04Z","timestamp":1545898324000},"page":"375-383","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development and Characterization of Olanzapine Loaded Poly(lactide-co-glycolide) Microspheres for Depot Injection: In vitro and In vivo Release Profiles"],"prefix":"10.2174","volume":"16","author":[{"given":"Fahad","family":"Pervaiz","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy and Alternative Medicines, The Islamia University of Bahawalpur, 63100, Bahawalpur, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmood","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Alternative Medicines, The Islamia University of Bahawalpur, 63100, Bahawalpur, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Acupuncture, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam","family":"Murtaza","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, COMSATS University Islamabad, Lahore Campus 60000, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"61","author":"Piccinelli M.","year":"1997","unstructured":"Piccinelli M, Homen FG.","journal-title":"Gender differences in the epidemiology of affective disorders and schizophrenia"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","volume":"52","author":"Gilbert P.L.","year":"1995","unstructured":"Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: A review of the literature.","journal-title":"Arch Gen Psychiatry"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1177\/107839039700300110","volume":"3","author":"Littrell K.H.","year":"1997","unstructured":"Littrell KH, Littrell SH. Therapeutic efficacy of olanzapine.","journal-title":"J Am Psychiatr Nurses Assoc"},{"key":"ref=4","first-page":"73","author":"Shen J.","year":"2012","unstructured":"Shen J, Burgess DJ. Drugs for Long Acting Injections and Implants. In: Jeremy, C.; Wright, D.J.B., ed. Long Acting Injections and Implants:","journal-title":"Springer"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/02652040802033913","volume":"25","author":"Nahata T.","year":"2008","unstructured":"Nahata T, Saini T. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine.","journal-title":"J Microencapsul"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/j.1552-4604.1987.tb02175.x","volume":"27","author":"Nayak R.K.","year":"1987","unstructured":"Nayak RK, Doose DR, Nair N. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.","journal-title":"J Clin Pharmacol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-2006-946703","volume":"39","author":"Bai Y-M.","year":"2006","unstructured":"Bai Y-M, Chen T, Wu B, Hung CH, Lin WK, Hu TM, Lin CY, Chou P. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.","journal-title":"Pharmacopsychiatry"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","volume":"167","author":"Kane J.M.","year":"2010","unstructured":"Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D. Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.","journal-title":"Am J Psychiatry"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-3659(99)00289-8","volume":"67","author":"Blanco-Pr\u00edeto M.J.","year":"2000","unstructured":"Blanco-Pr\u00edeto MJ, Besseghir K, Zerbe O, Andris D, Orsolini P, Heimgartner F, Merkle HP, Gander B. In vitro and evaluation of a somatostatin analogue released from PLGA microspheres.","journal-title":"J Control Release"},{"key":"ref=10","first-page":"1","author":"Burgess D.J.","year":"2012","unstructured":"Burgess DJ, Wright JC. An introduction to long acting injections and implants. In: Jeremy, C.; Wright, D.J.B., ed. Long Acting Injections and Implants: Springer,"},{"key":"ref=11","first-page":"3","author":"Perrin D.E.","year":"1997","unstructured":"Perrin DE, English JP. Polyglycolide and polylactide. In: Abraham, J.; Domb, J.K.; Wiseman, D. eds. Handbook of biodegradable polymers: Harwood Academic Publishers, Amsterdam:"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/pi.1697","volume":"54","author":"Alexis F.","year":"2005","unstructured":"Alexis F. Factors affecting the degradation and drug\u2010release mechanism of poly (lactic acid) and poly. [(lactic acid)-\u00ad\u2010co-\u00ad\u2010(glycolic acid)].","journal-title":"Polym Int"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1081\/PDT-100102043","volume":"5","author":"Kostanski J.W.","year":"2000","unstructured":"Kostanski JW, Thanoo B, DeLuca PP. Preparation, characterization, and evaluation of 1-and 4-month controlled release orntide PLA and PLGA microspheres.","journal-title":"Pharm Dev Technol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0168-3659(98)00056-X","volume":"55","author":"Cheng Y-H.","year":"1998","unstructured":"Cheng Y-H, Illum L, Davis S. A poly (D, L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol.","journal-title":"J Control Release"},{"key":"ref=15","first-page":"1","author":"Lewis D.","year":"1990","unstructured":"Lewis D. CControlled release of bioactive agents from lactide\/glycolide polymers. In: Chasin, M., ed. Biodegradable Polymers as Drug Delivery Systems. Marcel Dekker, New York:"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jconrel.2004.10.015","volume":"102","author":"Freitas S.","year":"2005","unstructured":"Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction\/evaporation: reviewing the state of the art of microsphere preparation process technology.","journal-title":"J Control Release"},{"key":"ref=17","volume":"2013","author":"D\u2019Souza S.","year":"2013","unstructured":"D\u2019Souza S, Faraj JA, Giovagnoli S, DeLuca PP. Preparation, characterization, and evaluation of olanzapine poly (D, Llactide- co-glycolide) microspheres.","journal-title":"J Pharm"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0142-9612(01)00291-5","volume":"23","author":"Hickey T.","year":"2002","unstructured":"Hickey T, Kreutzer D, Burgess D, Moussy F. Dexamethasone\/ PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices.","journal-title":"Biomaterials"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpharm.2006.01.034","volume":"313","author":"Fern\u00e1ndez-Carballido A.","year":"2006","unstructured":"Fern\u00e1ndez-Carballido A, Puebla P, Herrero-Vanrell R, Pastoriza P. Radiosterilisation of indomethacin PLGA\/PEG-derivative microspheres: Protective effects of low temperature during gamma-irradiation.","journal-title":"Int J Pharm"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Zhang Y.","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles.","journal-title":"AAPS J"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4314\/tjpr.v14i1.20","volume":"14","author":"Pervaiz F.","year":"2015","unstructured":"Pervaiz F, Ahmad M, Minhas MU, Sohail M. Development and validation of reverse phase high performance chromatography method for determination of olanzapine in microsample rat plasma: Application to preclinical pharmacokinetic study.","journal-title":"Trop J Pharm Res"},{"key":"ref=22","first-page":"80","volume":"8","author":"Khang G.","year":"2000","unstructured":"Khang G, Lee JH, Lee JW, Cho JC, Lee HB. Preparation and characterization of poly (lactide-co-glycolide) micro-spheres for the sustained release of AZT.","journal-title":"Korea Polym J"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0378-5173(01)00968-1","volume":"234","author":"Choi H.S.","year":"2002","unstructured":"Choi HS, Seo S-A, Khang G, Rhee JM, Lee HB. Preparation and characterization of fentanyl-loaded PLGA microspheres: release profiles.","journal-title":"Int J Pharm"},{"key":"ref=24","first-page":"167","author":"Wang Y.","year":"2012","unstructured":"Wang Y, Burgess DJ. Microsphere Technologies. In: Jeremy, C.; Wright, D.J.B., ed. Long acting injections and implants. Springer, London:"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11095-008-9562-y","volume":"25","author":"Champion J.A.","year":"2008","unstructured":"Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres.","journal-title":"Pharm Res"},{"key":"ref=26","first-page":"129","volume":"5","author":"Y\u00fcce M.","year":"2008","unstructured":"Y\u00fcce M, Canefe K. Indomethacin-loaded microspheres: preparation, characterization and in-vitro evaluation regarding ethylcellulose matrix material.","journal-title":"Turk J Pharm Sci"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1248\/cpb.57.1251","volume":"57","author":"Su Z.","year":"2009","unstructured":"Su Z, Sun F, Shi Y, Jiang C, Meng Q, Teng L, Li Y. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly (D, L-lactide-co-glycolide) microsphere.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0142-9612(99)00002-2","volume":"20","author":"Tracy M.","year":"1999","unstructured":"Tracy M, Ward K, Firouzabadian L, Wang Y, Dong N, Qian R, Zhang Y. Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres and in vitro.","journal-title":"Biomaterials"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/02652040500162196","volume":"22","author":"Fu X.","year":"2005","unstructured":"Fu X, Ping Q, Gao Y. Effects of formulation factors on encapsulation efficiency and release behaviour of huperzine A-PLGA microspheres.","journal-title":"J Microencapsul"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"Costa P.","year":"2001","unstructured":"Costa P, Sousa Lobo. J.M. Modeling and comparison of dissolution profiles.","journal-title":"Eur J Pharm Sci"},{"key":"ref=31","first-page":"110","volume":"60","author":"Peppas N.","year":"1984","unstructured":"Peppas N. Analysis of Fickian and non-Fickian drug release from polymers.","journal-title":"Pharm Acta Helv"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1590\/S1516-44462002000200007","volume":"24","author":"Vismari L.","year":"2002","unstructured":"Vismari L, Pires MLN, Benedito-Silva AA, Calil HM. Bioavailability of immediate and controlled release formulations of lithium carbonate.","journal-title":"Rev Bras Psiquiatr"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/168601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,28]],"date-time":"2019-07-28T16:12:34Z","timestamp":1564330354000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/168601\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201816666181227105930","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}